Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on the stock. JMP Securities reissued a “market outperform” rating and […]
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on the stock. JMP Securities reissued a “market outperform” rating and […]
